CSBR Stock - Champions Oncology, Inc.
Unlock GoAI Insights for CSBR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $56.94M | $50.16M | $53.87M | $49.11M | $41.04M |
| Gross Profit | $26.91M | $20.75M | $24.34M | $25.48M | $19.59M |
| Gross Margin | 47.3% | 41.4% | 45.2% | 51.9% | 47.7% |
| Operating Income | $4.85M | $-6,921,000 | $-4,449,000 | $607,000 | $366,000 |
| Net Income | $4.70M | $-7,276,000 | $-5,335,000 | $548,000 | $362,000 |
| Net Margin | 8.3% | -14.5% | -9.9% | 1.1% | 0.9% |
| EPS | $0.34 | $-0.54 | $-0.39 | $0.04 | $0.03 |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 12th 2024 | Craig Hallum | Upgrade | Buy | $6 |
Earnings History & Surprises
CSBREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 11, 2026 | $0.09 | — | — | — |
Q4 2025 | Dec 15, 2025 | $0.08 | $0.02 | -75.0% | ✗ MISS |
Q3 2025 | Sep 15, 2025 | $0.01 | $-0.03 | -400.0% | ✗ MISS |
Q3 2025 | Jul 23, 2025 | $0.06 | $-0.13 | -316.7% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.01 | $0.31 | +3200.0% | ✓ BEAT |
Q4 2024 | Dec 11, 2024 | $0.01 | $0.05 | +400.0% | ✓ BEAT |
Q3 2024 | Sep 11, 2024 | $0.02 | $0.11 | +466.7% | ✓ BEAT |
Q3 2024 | Jul 18, 2024 | $-0.16 | $-0.01 | +93.8% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.06 | $-0.19 | -216.7% | ✗ MISS |
Q4 2023 | Dec 12, 2023 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q3 2023 | Sep 13, 2023 | $-0.10 | $-0.19 | -90.0% | ✗ MISS |
Q3 2023 | Jul 24, 2023 | $-0.12 | $-0.19 | -58.3% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.06 | $-0.18 | -200.0% | ✗ MISS |
Q4 2022 | Dec 13, 2022 | $-0.00 | $-0.00 | -100.0% | ✗ MISS |
Q3 2022 | Sep 8, 2022 | $-0.01 | $-0.02 | -300.0% | ✗ MISS |
Q3 2022 | Jul 21, 2022 | $-0.01 | $-0.03 | -220.2% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $0.03 | $0.05 | +100.0% | ✓ BEAT |
Q4 2021 | Dec 13, 2021 | $0.01 | $0.02 | +300.0% | ✓ BEAT |
Q3 2021 | Sep 13, 2021 | $-0.00 | $-0.01 | -200.3% | ✗ MISS |
Q3 2021 | Jul 22, 2021 | $0.01 | $-0.04 | -500.0% | ✗ MISS |
Frequently Asked Questions about CSBR
What is CSBR's current stock price?
What is the analyst price target for CSBR?
What sector is Champions Oncology, Inc. in?
What is CSBR's market cap?
Does CSBR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CSBR for comparison